96 results
Page 4 of 5
10-K
EX-10.33
jrqr3zx j8oc4v5xpvm
1 Mar 21
Annual report
12:00am
10-K
EX-10.29
9r335o
1 Mar 21
Annual report
12:00am
10-K
EX-10.20
daz ovvjy3dngyvq
1 Mar 21
Annual report
12:00am
10-K
EX-10.30
isfb21i4o
1 Mar 21
Annual report
12:00am
8-K
EX-99.1
awpi42dbad17h5 jeiqq
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
424B5
4fpvoz 8cybi5dd6g
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-1.1
unvk1u qwf
21 Sep 20
Current report (foreign)
4:15pm
424B5
uzd0li
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
mku1et941o8
11 Sep 20
Current report (foreign)
8:16am
6-K
EX-99.1
gn3eavkvbf
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
8c51r5bp 3u6ct
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
424B2
of3 aw2vtjkudtx
24 Jan 20
Prospectus for primary offering
7:24am
6-K
EX-1.1
8hlbli9c
22 Jan 20
Current report (foreign)
11:58am
6-K
7k1j8s dqumrroq
21 Jan 20
Current report (foreign)
5:31pm
424B5
y675ye4fqfgljahnr3
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
47d3bwu3w9kj0l
11 Jun 19
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
7:00am
424B2
sgpov
6 May 19
Prospectus for primary offering
6:04am